LUCINAE Registry: Thoracic Cancers During Pregnancy (LUCINAE)
LUCINAE: LUng and Thoracic Cancers In pregNAncy rEgistry
The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives.
Because thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers.
The results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
The LUCINAE Registry (LUng and thoracic Cancers In pregNAncy rEgistry) is an international, multicenter registry with retrospective and prospective (ambispective) data collection.
The incidence of cancers in younger individuals is increasing, and due to delayed maternal age and other factors, more patients are diagnosed with cancer during pregnancy or become pregnant during or after cancer treatment. Thoracic cancers during pregnancy are rare events, but they are associated with high maternal morbidity and mortality and may have important implications for fetal outcomes.
Currently, there is a lack of specific clinical guidelines for the management of thoracic cancers during pregnancy, and limited data are available regarding the safety and outcomes of anticancer treatments in this setting. Existing registries are not specific for thoracic malignancies, and available evidence is based on a limited number of reported cases.
The LUCINAE Registry aims to collect comprehensive data on biologically female and male patients with thoracic cancers who are expecting a child. The primary objective is to describe clinical and biological characteristics, family history, treatments, and maternal and fetal outcomes.
The study includes two cohorts:
Cohort A (retrospective): patients included after death, with data collected from medical records.
Cohort B (prospective): patients currently treated or diagnosed during the enrollment period, with longitudinal follow-up and periodic data updates.
Eligible participants include women diagnosed with thoracic cancer during pregnancy, women who become pregnant during active disease or within 5 years after treatment, and men receiving active oncological treatment at the time their partner conceives.
Data collected include patient characteristics (demographics, medical history, genetic information), tumor characteristics (stage, histology, biomarker status), diagnostic procedures, treatment details (including systemic therapies, surgery, and radiotherapy), pregnancy characteristics, complications, and maternal and fetal outcomes. Follow-up data are collected at multiple timepoints up to 5 years after delivery, when available.
Analyses will be primarily descriptive and will evaluate clinical and biological characteristics, treatment patterns, and outcomes. Correlation analyses between treatments and outcomes will also be performed. The study does not impose any intervention, and all treatment decisions are made by the treating physicians.
The registry is intended to improve understanding of thoracic cancers in the context of pregnancy, to support future research, and to contribute to the development of clinical management strategies for this patient population.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Martina Imbimbo
- Puhelinnumero: +41918119631
- Sähköposti: Martina.Imbimbo@eoc.ch
Tutki yhteystietojen varmuuskopiointi
- Nimi: Luigi Tortola
- Puhelinnumero: +41 91 811 96 68
- Sähköposti: luigi.tortola@eoc.ch
Opiskelupaikat
-
-
-
Baden, Sveitsi
- Rekrytointi
- Kantonsspital Baden
-
Ottaa yhteyttä:
- Sacha Rothschild, Site Investigator
-
Bellinzona, Sveitsi
- Rekrytointi
- Istituto Oncologico della Svizzera Italiana (IOSI)
-
Ottaa yhteyttä:
- Martina Imbimbo, Project Leader
-
Geneva, Sveitsi
- Rekrytointi
- Geneva University Hospital (HUG)
-
Ottaa yhteyttä:
- Alfredo Addeo, Site Investigator
-
Winterthur, Sveitsi
- Rekrytointi
- Kantonsspital Winterthur
-
Ottaa yhteyttä:
- Laetitia Mauri, Site Investigator
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
1. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including:
- Patients receiving a diagnosis of thoracic cancer during pregnancy
- Patients who became pregnant while having active thoracic cancer
- Patients previously treated for a thoracic cancer and becoming pregnant in the 5 years following end of treatment OR Men with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities), who were undergoing active oncological treatment at the time their partner conceived their child.
- 2. Available information about pregnancy outcomes
- 3. Age ≥ 18 years
Exclusion Criteria:
- 1. Patient missing data about thoracic cancer stage and diagnosis
- 2. For retrospective patients, documented refusal to the use of clinical data for research purposes
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Cohort A
Retrospective patients: patients who are included in the registry only after death.
|
|
Cohort B
Prospective patients: patients who are currently treated at the participating site or will be diagnosed during the enrollment
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Timing of diagnosis
Aikaikkuna: At the moment of patient enrolment
|
Timing of cancer diagnosis with respect to the onset of pregnancy.
|
At the moment of patient enrolment
|
|
Modality of diagnosis
Aikaikkuna: At the moment of patient enrolment
|
Method used for cancer diagnosis.
|
At the moment of patient enrolment
|
|
Duration of treatment
Aikaikkuna: Throughout study participation, up to 5 years after delivery.
|
Duration of the treatment received during the pregnancy
|
Throughout study participation, up to 5 years after delivery.
|
|
Maternal outcome
Aikaikkuna: At the conclusion of pregnancy.
|
Survival of the mother at the end of gestation.
|
At the conclusion of pregnancy.
|
|
Fetal outcome
Aikaikkuna: At the conclusion of pregnancy.
|
Survival of the fetus at the end of gestation.
|
At the conclusion of pregnancy.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Parental overall survival
Aikaikkuna: From thoracic cancer diagnosis until 5 years after delivery.
|
Overall survival of biologically female and male thoracic cancer patients included in the registry, defined as time from thoracic cancer diagnosis to death from any cause.
|
From thoracic cancer diagnosis until 5 years after delivery.
|
|
Offspring's overall survival
Aikaikkuna: From birth until 5 years after birth.
|
Overall survival of the offspring of enrolled parents, defined as time from birth to death from any cause.
|
From birth until 5 years after birth.
|
|
Pregnancy complications
Aikaikkuna: From pregnancy diagnosis to 1 month after delivery.
|
Incidence of complications associated with the pregnancy.
|
From pregnancy diagnosis to 1 month after delivery.
|
|
Gestational age at delivery
Aikaikkuna: At the conclusion of pregnancy.
|
Gestational age of the fetus at the moment of delivery.
|
At the conclusion of pregnancy.
|
|
Congenital abnormalities
Aikaikkuna: From birth to 30 days after birth.
|
Proportion of newborns diagnosed with congenital abnormalities.
|
From birth to 30 days after birth.
|
|
Neonatal intensive care unit (NICU) admission
Aikaikkuna: From birth to 30 days after birth.
|
Proportion of newborns admitted to neonatal intensive care unit after birth.
|
From birth to 30 days after birth.
|
|
Apgar score
Aikaikkuna: Measured 1 minute and 5 minutes after birth.
|
Measurement of Apgar score to assess the newborn's vital signs and immediate need for medical intervention.
|
Measured 1 minute and 5 minutes after birth.
|
|
Oncologic treatment exposure
Aikaikkuna: Throughout pregnancy until 5 years after delivery.
|
Type, timing, and toxicity of anticancer treatments administered during and after pregnancy.
|
Throughout pregnancy until 5 years after delivery.
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- LUCINAE Registry
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .